MARKET

ARVN

ARVN

Arvinas
NASDAQ
41.33
+0.33
+0.80%
After Hours: 40.97 -0.36 -0.87% 17:59 03/27 EDT
OPEN
41.50
PREV CLOSE
41.00
HIGH
41.55
LOW
40.34
VOLUME
341.40K
TURNOVER
0
52 WEEK HIGH
53.08
52 WEEK LOW
13.57
MARKET CAP
2.81B
P/E (TTM)
-6.2451
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ARVN last week (0318-0322)?
Weekly Report · 3d ago
Arvinas: Statement of changes in beneficial ownership of securities
Press release · 6d ago
Arvinas gets new chief medical head
Healthcare Arvinas gets new chief medical head. Noah Berkowitz, M.D., Ph.D. Will lead the ongoing clinical development of oncology and neuroscience programs for the company. The company also announced that Ron Peck will be leaving to pursue other opportunities.
Seeking Alpha · 03/19 06:19
Arvinas Appoints New Chief Medical Officer for Clinical Programs
TipRanks · 03/18 21:04
Press Release: Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Arvinas Appoints Noah Berkowitz, M.D., Ph.D. As Chief Medical Officer. Dr. Berkowitz will lead the ongoing clinical development of Arvinas' protein degrader programs in oncology and neuroscience. The Company also announced the departure of Ron Peck, M.,D. From the company. Arvin as is a clinical-stage company creating a new class of drugs based on targeted protein degradation.
Dow Jones · 03/18 20:40
Weekly Report: what happened at ARVN last week (0311-0315)?
Weekly Report · 03/18 09:05
Weekly Report: what happened at ARVN last week (0304-0308)?
Weekly Report · 03/11 09:05
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
More
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.

Webull offers Arvinas Inc stock information, including NASDAQ: ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.